Previous studies assessed hepatic expression of chemerin and its gene in nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) [41] and animal models [9, 42]. This evidence concerns the gene RARRES2 and metabolic dysfunction-associated steatotic liver disease.